Clinical trials: Refractory Immune-mediated Necrotizing Myopathy
- Condition Refractory Immune-mediated Necrotizing Myopathy
- Funder type Industry (pharma, biotech, devices)
Idiopathic Inflammatory Myopathies
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)
- Trial name
- NCT06665256
- Testing
- Rapcabtagene autoleucel, Active Comparator Option
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Refractory Immune-mediated Necrotizing Myopathy
A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy
This is an open-label, single-arm Phase I/II clinical study to evaluate the efficacy and safety of Eque-cel Injection in patients with refractory immune-mediated necrotizing myopathy.
- Trial name
- NCT07752264
- Testing
- Equecabtagene Autoleucel Injection (Eque-cel)
- Where
- 4 sites in China
- Volunteers
- 27 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.